Baiyunshan: Subsidiary's Shujin Jianyao Wan Receives Clinical Trial Approval for New Indication

Baiyunshan announced that its subsidiary, Guangzhou Baiyunshan Chenliji Pharmaceutical Factory Co., Ltd., has received the Drug Clinical Trial Approval Notice approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of the already-marketed traditional Chinese medicine compound preparation Shujin Jianyao Pills for the treatment of lumbar disc herniation with liver and kidney deficiency and wind-dampness stasis obstruction syndrome. Shujin Jianyao Pills is an exclusive product of Chenliji Pharmaceutical Factory. This application is for adding a new indication. As of the announcement date, approximately RMB 22.0540 million has been invested in research and development for this project. In 2025, the sales revenue of Shujin Jianyao Pills from Chenliji Pharmaceutical Factory was RMB 119.7184 million.